Webster A D, Brown D, Franz A, Dusheiko G
Department of Clinical Immunology, Royal Free Hospital, London, UK.
Clin Exp Immunol. 1996 Jan;103(1):5-7. doi: 10.1046/j.1365-2249.1996.916612.x.
Concern over sporadic hepatitis C virus (HCV) infection from treatment with contaminated immunoglobulin in patients with immunodeficiency prompted use to screen serum from 44 patients for HCV RNA. We found no evidence of either horizontal or iatrogenic infection in our Clinic, except in two patients known to have received contaminated batches, and in one who had had regular plasma infusions. Thus, common variable immunodeficiency (CVID) patients in England do not have a high incidence of HCV infection despite exposure to various immunoglobulin products. This contrasts with the recently reported high prevalence in similar patients in Italy. Although our data reinforce the impression that both intramuscular and current licensed i.v. preparations in the UK are safe, manufacturers should be encouraged to PCR screen all batches of immunoglobulin for HCV.
对免疫缺陷患者使用受污染免疫球蛋白治疗引发的散发性丙型肝炎病毒(HCV)感染的担忧,促使我们对44例患者的血清进行HCV RNA筛查。我们在诊所未发现水平感染或医源性感染的证据,仅有两名已知接受过受污染批次免疫球蛋白的患者以及一名定期接受血浆输注的患者除外。因此,尽管接触了各种免疫球蛋白产品,但英国的常见可变免疫缺陷(CVID)患者HCV感染发生率并不高。这与最近报道的意大利类似患者中的高患病率形成对比。尽管我们的数据强化了英国肌肉注射和目前获得许可的静脉注射制剂均安全的印象,但仍应鼓励制造商对所有批次的免疫球蛋白进行HCV的PCR筛查。